Table 2.
The role of IL-6 in metabolic control in rodents.
| Species/Description | Treatment | Observed Effects | Reference |
|---|---|---|---|
| Mice/IL-6 KO | n.d. | Mature-onset obesity: Increased weight of subcutaneous fat pad | [18] |
| Mice/IL-6 KO; HFD | Intracerebroventricular IL-6 injection for 2 weeks | Decreased relative weight of mesenteric and retroperitoneal fat pads; Suppressed body weight | [32] |
| Mice/HFD; IL-6 transgenic mice (with sustained release of human IL-6) | n.d. | Decreased food intake; Increased energy expenditure; Reduced visceral fat on normal chow and free from HFD-induced obesity | [33] |
| Rat/male | Direct delivery of recombinant adeno-associated viral vector expressing murine IL-6 into hypothalamus | Suppressed weight gain and visceral adiposity | [34] |
| Mice/HFD-induced obese mice | Delivery of pLIVE-IL-6 plasmid expressing murine IL-6 | Reduction in body weight; Increased expression of enzymes involved in FA oxidation | [19] |
| Mice/Double transgenic mice co-expressing IL-6 and soluble IL-6 receptors | n.d. | Reduced body weight; Decreased body fat | [35] |
| Mice/IL-6 KO; female; HFD | n.d. | Decreased body weight gain and fat mass | [36] |
KO, Knock out; HFD, High-fat diet; n.d., No data.